Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
Post date: 2026-07-24 02:52:00
Views: 0
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
Please click Here to read the full story.
 
Other Top and Latest Questions:
Jim Cramer's top 10 things to watch in the stock market Thursday
Comcast earnings highlight NBCUniversal strength ahead of planned split
China's Geely to make EVs at Ford plant in Spain under new joint venture
UniCredit CEO tells CNBC acquisition of Commerzbank could happen in fourth quarter
Please explain Mamdani's focus/statements on Netanyahu
Weird Donation Split?
Alphabet and Tesla test Wall Street's patience as AI spending overshadows growth
Movie: Troy
The Devil Judge: The Yellow Porsche
Brent crude tops $100 a barrel. How the next stop could be $120